CHRS

Lucentis® (ranibizumab) Biosimilar

Ophthalmology

Phase 3 (BLA Filing)

Exp Date

H2 2020

Amp Volatility Score

Catalyst Info & Data Links

TITLE: Lucentis® (ranibizumab) Biosimilar in Ophthalmology - BLA Filing


WHAT IS THE CATALYST EVENT?

  • BLA Filing


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • H2 2020


PRIOR DATA/EVENTS

PRESS RELEASE

POSTERS


PRESENTATIONS


PUBLICATIONS



MECHANISM OF ACTION / RATIONALE

  • Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF110. VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, macular edema following RVO, and DME. The binding of ranibizumab to VEGF-A prevents the interaction of VEGF-A with its receptors (VEGFR1 and VEGFR2) on the surface of endothelial cells, reducing endothelial cell proliferation, vascular leakage, and new blood vessel formation.



Updated by HC

#CHRS, #Lucentis®, #Ranibizumab, #Biosimilar, #Ophthalmology, #BLA

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon